TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15033894
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg (Group RO)
Study: 15033894
Drug: Dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen trometamol 25 mg (Group DE)
Study: 11392449
Drug: Oral docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral docetaxel in combination with cyclosporin A
Study: 11392449
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel in combination with cyclosporin A
Study: 11392449
Drug: Oral route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral route for both taxanes
Study: 7946934
Drug: CNS 1102,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS 1102, maximum tolerated dose 30 micrograms kg‐1
Study: 7946934
Drug: CNS 1102,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS 1102, administered as a 15 min intravenous infusion
Study: 20418304
Drug: Constant infusion
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant infusion rate group (normal saline 0.9% at an infusion rate 10 to 12 mL . kg(‐1) . h(‐1))
Study: 18069215
Drug: Oral oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestrogen therapy (2 mg daily)
Study: 18069215
Drug: Transdermal oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal oestrogen therapy (0.05 mg daily)
Study: 9713640
Drug: comparator agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparator agents (placebo or salbutamol)
Study: 27822702
Drug: Daily WeChat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily WeChat services on cell phone for adherence to corticosteroid nasal spray treatment.
Study: 27822702
Drug: Budesonide aqueous
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide aqueous nasal spray 128 µg bid (given to all subjects).
Study: 25471080
Drug: Subcutaneous specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous specific immunotherapy (SIT) with PURETHAL® Mites for 8 months
Study: 25471080
Drug: Medication to
Normalized name: Acne Medication Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication to treat symptoms only (Control group)
Study: 22304836
Drug: Daily grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily grapefruit (1/2 fresh Rio-Red grapefruit with each meal, 3× daily for 6 weeks)
Study: 19513811
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of tetrahydrobiopterin (BH(4))
Study: 16336497
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg tegaserod
Study: 11039962
Drug: Lipid lowering
Normalized name: Lipid lowering agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering drugs (duration: five to seven years)
Study: 11039962
Drug: Lipid lowering
Normalized name: Lipid lowering agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid lowering drugs
Study: 6863582
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 25 mg
Study: 6863582
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 75 mg
Study: 6863582
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine 100 mg
Study: 30613058
Drug: Communication Empowerment
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication Empowerment Program based on Situated Learning Theory (8 sessions, twice a week, 2 hours each)
Study: 26467666
Drug: HPV16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16/18 vaccine (Cervarix)
Study: 25178568
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (<40 g/d)
Study: 25178568
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (<30% of daily energy intake from total fat)
Study: 23043943
Drug: Flutamide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (administered prenatally between Days 80 and 88 of gestation and neonatally between Days 2 and 10 postnatally)
Study: 23043943
Drug: Flutamide (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (administered prenatally and neonatally)
Study: 15944796
Drug: 5-fluorouracil/mitomycin adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/mitomycin adjuvant chemotherapy
Study: 31045947
Drug: Antiresorptive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive drugs (i.e. bisphosphonates)
Study: 31045947
Drug: Bone anabolic
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone anabolic drugs (i.e. teriparatide)
Study: 28541802
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment for co-occurring PTSD and substance use disorder
Study: 21457842
Drug: 2.5° buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5° buccal root torque
Study: 21457842
Drug: 15° buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15° buccal root torque
Study: 17213476
Drug: Pioglitazone (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (45 mg for 21 days)
Study: 7943597
Drug: Postoperative hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative hepatic perfusion chemotherapy via hepatic artery and portal vein with 5-fluorouracil (125 mg/d) for 28 to 35 days
Study: 2835743
Drug: Combined measles,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined measles, mumps, rubella, and varicella vaccine
Study: 26195058
Drug: GA40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA40 (40 mg/mL three-times weekly)
Study: 26195058
Drug: GA20 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA20 (20 mg/mL daily)
Study: 23877462
Drug: Vertebral augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertebral augmentation procedures with advanced imaging (MRI, CT, or bone scan)
Study: 23877462
Drug: Vertebral augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vertebral augmentation procedures with Workers compensation
Study: 15078379
Drug: 0.45 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 mg.kg(‐1) rocuronium bromide
Study: 15078379
Drug: 0.6 mg.kg(‐1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg.kg(‐1) rocuronium bromide
Study: 10903790
Drug: O +
Normalized name: Acti-Lipo + Pyridoxine Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: O + M + L
Study: 9285652
Drug: 480 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg/day diltiazem (morning dosing)
Study: 9285652
Drug: 480 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 480 mg/day diltiazem (evening dosing)
Study: 8324395
Drug: Seldane-D (terfenadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seldane-D (terfenadine 60 mg + pseudo-ephedrine 120 mg)
Study: 8324395
Drug: Pseudo-ephedrine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudo-ephedrine (120 mg)
Study: 25980735
Drug: 25-minute interval
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-minute interval between tumescent anesthetic solution infiltration and start of surgery
Study: 25980735
Drug: 15-minute interval
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-minute interval between tumescent anesthetic solution infiltration and start of surgery
Study: 25980735
Drug: 10-minute interval
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-minute interval between tumescent anesthetic solution infiltration and start of surgery
Study: 21813223
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at predicted effect site concentrations of 0.4, 0.8, 1.2, 1.6, and 2.0 μg/mL
Study: 21813223
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at predicted effect site concentrations of 1.6 and 2.0 μg/mL
Study: 21813223
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at predicted effect site concentration of 2.0 μg/mL
Study: 21813223
Drug: Propofol at
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol at predicted effect site concentration of 1.2 μg/mL or less
Study: 19231302
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with intravenous midazolam and placebo throat spray (midazolam group)
Study: 19231302
Drug: Placebo sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sedation and placebo throat spray (placebo group)
Study: 16698410
Drug: Aminophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (250 mg, and an additional 250 mg if necessary)
Study: 11798062
Drug: Prospective, subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prospective, subgroup specific therapy efficacy
Study: 9669257
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no L-arginine)
Study: 8077575
Drug: Soy-based formula
Normalized name: Soy-based formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based formula with 2.91 g protein/100 kcal (IS)
Study: 8077575
Drug: Soy-based formula
Normalized name: Soy-based formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based formula with 2.45 g protein/100 kcal (EF)
Study: 364781
Drug: Photodynamic inactivation
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic inactivation (neutral red 1% solution + 15-min exposure to 40 watt light of 440-550 nm)
Study: 364781
Drug: Idoxuridine (IDU)
Normalized name: Idoxuridine
DrugBank: Idoxuridine (DB00249)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Idoxuridine (IDU) ointment
Study: 28851784
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 supplementation (50 µg daily from early pregnancy until 6 months postpartum)
Study: 28851784
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily from early pregnancy until 6 months postpartum)
Study: 24286136
Drug: Brodalumab (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab (50 mg, 140 mg, or 210 mg subcutaneously every two weeks for 6 doses; or 420 mg or 700 mg intravenously every 4 weeks for two doses)
Study: 21062790
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) with propofol‐remifentanil
Study: 18467185
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 1500 microg every 4 weeks with oral ribavirin 800 mg/day for 24 weeks
Study: 18467185
Drug: Albinterferon alfa-2b
Normalized name: albinterferon alfa-2b
DrugBank: Albinterferon Alfa-2B (DB05396)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon alfa-2b 1500 microg every 2 weeks with oral ribavirin 800 mg/day for 24 weeks
Study: 8375243
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (10 g)
Study: 8375243
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose (20 g)
Study: 8375243
Drug: Subcutaneous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous glucagon (1.0 mg)
Study: 8375243
Drug: Oral Ala
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ala (40 g)
Study: 8375243
Drug: Oral terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbutaline (5.0 mg)
Study: 29480440
Drug: Short-term lotteries
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term lotteries in combination with an additional long-term lottery after 26 weeks
Study: 27019158
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg single dose after high-fat breakfast
Study: 27019158
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg single dose in fasting state
Study: 27019158
Drug: Faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faldaprevir 240 mg single dose with omeprazole 40 mg q.d. for 5 days
Study: 21921426
Drug: Aprepitant 80
Normalized name: aprepitant 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 80 mg preoperative dose
Study: 16612448
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg twice a day for one week
Study: 10951629
Drug: Domestic glutathione
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic glutathione (GSH) - continuous infusion of 600g daily for 30 days
Study: 10951629
Drug: TAD -
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAD - same dosage, course and route as GSH
Study: 8831579
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of conventional techniques and Octreoscan scintigraphy
Study: 22170706
Drug: Exercise-induced β-endorphin
Normalized name: beta-endorphin human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-induced β-endorphin levels above 25 pg/ml (n = 7)
Study: 20158290
Drug: Triazolam (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125, 0.25 mg/70 kg)
Study: 20158290
Drug: Alcohol (0.40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.40, 0.80 g/kg)
Study: 16872896
Drug: 0.2% Lavasept
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% Lavasept solution (n=28)
Study: 16872896
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution (n=22)
Study: 15641497
Drug: Xylitol-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylitol-containing chewing gum (65% xylitol), 6 pieces daily for 14 days
Study: 15641497
Drug: Sorbitol-containing chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbitol-containing chewing gum (control), 6 pieces daily for 14 days
Study: 7780067
Drug: Epidural meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural meperidine infusion
Study: 7780067
Drug: Intravenous PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous PCA meperidine infusion
Study: 2277298
Drug: Azathioprine and
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine and steroids with 28 days of intravenous antithymocyte globulin
Study: 2277298
Drug: Cyclosporine and
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine and low-dose steroids
Study: 2277298
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (not specified)
Study: 416647
Drug: Reduced dose
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced dose irradiation, 3,000 rads followed by chemotherapy with Thio‐tepa
Study: 28691417
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied during PCI at a dose of 9 J/cm2
Study: 23321244
Drug: Double antibiotic
Normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double antibiotic paste (bipaste)
Study: 23321244
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic paste (tripaste)
Study: 22129567
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (ferrous succinate, 200 mg [100 mg × 2])
Study: 22129567
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (Sulifei, 200 mg [100 mg × 2])
Study: 15663236
Drug: Ropivacaine mesylate
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine mesylate (15 ml of 8.94 mg/ml for anesthesia and 2.374 mg/ml for analgesia)
Study: 15663236
Drug: Ropivacaine hydrochloride
Normalized name: Ropivacaine Hydrochloride
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine hydrochloride (15 ml of 7.5 mg/ml for anesthesia and 2 mg/ml for analgesia)
Study: 20839572
Drug: Placentrex injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placentrex injection combined with antimicrobial therapy (Group I)
Study: 20839572
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy alone (Group II)
Study: 10604829
Drug: Neoral capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral capsules, 5 mg/kg twice a day for 12 weeks
Study: 10604829
Drug: Sandimmune (SIM)
Normalized name: Sandimmune
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandimmune (SIM) capsules, 5 mg/kg twice a day for 12 weeks
Study: 10604829
Drug: Neoral capsules
Normalized name: cyclosporine Oral Capsule [Neoral]
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral capsules
Study: 1663301
Drug: Inactivated hepatitis
Normalized name: Inactivated hepatitis A vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated hepatitis A virus vaccine
Study: 6752738
Drug: Physostigmine (0.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (0.0, 0.125, 0.25, and 0.5 mg given intravenously over 30 min)
Study: 29180278
Drug: Amikacin 25
Normalized name: amikacin 250 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amikacin 25 mg/kg
Study: 21351255
Drug: Full-length adiponectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-length adiponectin treatment
Study: 18036907
Drug: High-dose insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose insulin therapy (titrated intravenous insulin infusion)
Study: 18036907
Drug: Standard high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard high-dose systemic insulin infusion at 5 mU/kg/min
Study: 16286438
Drug: rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (4 mg daily)
Study: 12128237
Drug: Clonazepam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5 mg)
Study: 9823789
Drug: Thrombolytic regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic regimens (bolus thrombolysis, glycoprotein IIb/IIIa inhibition, low‐molecular‐weight heparin)
Study: 9823789
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering with statin drugs
Study: 8043977
Drug: Fenofibrate treatment
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate treatment for 12 weeks
Study: 3377212
Drug: 0.42% NaHCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42% NaHCO3 solution added to bupivacaine
Study: 29174310
Drug: Vinorelbine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine plus cisplatin (vinorelbine 25 mg/m2 on days 1 and 8 plus cisplatin 75 mg/m2 on day 1 every 3 weeks for four cycles)
Study: 16281510
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/d) and acetyl-L-carnitine (1 g/d)
Study: 16281510
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (100 mg) plus Vitamin C (100 mg)
Study: 9121974
Drug: Transvenous lead
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transvenous lead linked to a patch electrode
Study: 3552909
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS) 1-2 g
Study: 28906574
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of picosecond laser (1 064 and 595 nm) and 2% hydroquinone (HQ) cream for 7 weeks and 5 weeks of laser treatment (weekly).
Study: 28906574
Drug: 2% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% hydroquinone (HQ) cream alone for 7 weeks.
Study: 28906574
Drug: Picosecond laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picosecond laser treatment side at week 7.
Study: 25920470
Drug: Neurophysiological-based conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurophysiological-based conventional therapy
Study: 21742943
Drug: Algae‐derived DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Algae‐derived DHA (12 g·ewe(‐1)·d(‐1))
Study: 20003384
Drug: Intensive sexological
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive sexological treatment
Study: 20003384
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (waiting list)
Study: 17100679
Drug: AV sequential
Normalized name: AVS-100
DrugBank: AVS-100 (DB18068)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV sequential pacing mode
Study: 9329422
Drug: Topical iodine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical iodine-containing antiseptics (n = 73)
Study: 9329422
Drug: Topical iodine-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical iodine-containing antiseptics (n = 24)
Study: 8204876
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human interleukin‐1 beta (rhIL‐1 beta) at 0.01, 0.02, 0.05 microgram/kg administered by intravenous infusion once a day for 5 doses.
Study: 28858553
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal Bupivacaine (LB) 133 mg/10 mL